About Intellectual Property IP Training Respect for IP IP Outreach IP for… IP and... IP in... Patent & Technology Information Trademark Information Industrial Design Information Geographical Indication Information Plant Variety Information (UPOV) IP Laws, Treaties & Judgements IP Resources IP Reports Patent Protection Trademark Protection Industrial Design Protection Geographical Indication Protection Plant Variety Protection (UPOV) IP Dispute Resolution IP Office Business Solutions Paying for IP Services Negotiation & Decision-Making Development Cooperation Innovation Support Public-Private Partnerships AI Tools & Services The Organization Working with WIPO Accountability Patents Trademarks Industrial Designs Geographical Indications Copyright Trade Secrets WIPO Academy Workshops & Seminars IP Enforcement WIPO ALERT Raising Awareness World IP Day WIPO Magazine Case Studies & Success Stories IP News WIPO Awards Business Universities Indigenous Peoples Judiciaries Genetic Resources, Traditional Knowledge and Traditional Cultural Expressions Economics Finance Intangible Assets Gender Equality Global Health Climate Change Competition Policy Sustainable Development Goals Frontier Technologies Mobile Applications Sports Tourism PATENTSCOPE Patent Analytics International Patent Classification ARDI – Research for Innovation ASPI – Specialized Patent Information Global Brand Database Madrid Monitor Article 6ter Express Database Nice Classification Vienna Classification Global Design Database International Designs Bulletin Hague Express Database Locarno Classification Lisbon Express Database Global Brand Database for GIs PLUTO Plant Variety Database GENIE Database WIPO-Administered Treaties WIPO Lex - IP Laws, Treaties & Judgments WIPO Standards IP Statistics WIPO Pearl (Terminology) WIPO Publications Country IP Profiles WIPO Knowledge Center WIPO Technology Trends Global Innovation Index World Intellectual Property Report PCT – The International Patent System ePCT Budapest – The International Microorganism Deposit System Madrid – The International Trademark System eMadrid Article 6ter (armorial bearings, flags, state emblems) Hague – The International Design System eHague Lisbon – The International System of Appellations of Origin and Geographical Indications eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange Mediation Arbitration Expert Determination Domain Name Disputes Centralized Access to Search and Examination (CASE) Digital Access Service (DAS) WIPO Pay Current Account at WIPO WIPO Assemblies Standing Committees Calendar of Meetings WIPO Webcast WIPO Official Documents Development Agenda Technical Assistance IP Training Institutions COVID-19 Support National IP Strategies Policy & Legislative Advice Cooperation Hub Technology and Innovation Support Centers (TISC) Technology Transfer Inventor Assistance Program WIPO GREEN WIPO's Pat-INFORMED Accessible Books Consortium WIPO for Creators WIPO Translate Speech-to-Text Classification Assistant Member States Observers Director General Activities by Unit External Offices Job Vacancies Procurement Results & Budget Financial Reporting Oversight
Arabic English Spanish French Russian Chinese
Laws Treaties Judgments Browse By Jurisdiction

Japan

JP010-j

Back

2009 (Gyo-Hi) 326, Minshu Vol. 65, No. 3

Date of Judgment: April 28, 2011

 

Issuing Authority: Supreme Court

 

Level of the Issuing Authority: Final Instance

 

Type of Procedure: Judicial (Administrative)

 

Subject Matter: Patent (Inventions)

 

Main text of the judgment (decision):

 

1.The final appeal is dismissed.

 

2.The appellant of final appeal shall bear the cost of the final appeal.

 

Reasons:

 

Concerning the reasons for acceptance of final appeal argued by the agents appointed for final appeal, SUDO Noriaki, et al.

1. In this case, the appellee of final appeal, who holds a patent right for Patent No. 3134187 (this patent and patent right shall hereinafter be referred to as the "Patent" and "Patent Right," respectively), seeks revocation of the trial decision issued by the Japan Patent Office (JPO) dismissing the appellee's request for a trial against the examiner's decision to refuse the appellee's application for registration of extension of the duration of the Patent Right.

2. The outline of the facts legally determined by the court of prior instance is as follows.

(1) The Patent (containing 22 claims) was based on the patent application filed on March 6, 1997, for the invention entitled "controlled release composition," and was registered on December 1, 2000.

The invention claimed in the Patent relates to a controlled release composition wherein the core containing medicinal substances is coated by a coating agent that contains a water-insoluble substance, a certain hydrophilic substance, and a certain cross-linked acrylic polymer.

(2) On September 30, 2005, the appellee obtained approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act (hereinafter referred to as the "Disposition") with regard to the pharmaceutical product called "Pacif Capsules 30mg" (hereinafter referred to as the "Pharmaceutical Product"). The Pharmaceutical Product contains morphine hydrochloride as its active ingredient, and has the effect and efficacy of a painkiller for various types of cancers that cause a medium to high level of pain.

(3) Prior to the Disposition, another approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act had been issued to another pharmaceutical product called "OPSO (oral solution) 5mg/10mg" which has the same active ingredient as well as effect and efficacy as those of the Pharmaceutical Product (this approval and pharmaceutical product shall hereinafter be referred to as the "Earlier Disposition" and "Earlier Pharmaceutical Product," respectively). The Earlier Pharmaceutical Product is not included in the technical scope of the patented invention specified by any of the claims for the Patent Right.

(4) On December 16, 2005, the appellee filed an application for registration of extension of the duration of the Patent Right, on the grounds that the appellee had been unable to work the patented invention based on the Patent Right during a certain period of time due to the necessity to obtain the Disposition, but the JPO examiner issued a decision to refuse this application. Dissatisfied with this decision, the appellee filed a request for a trial against the examiner's decision of refusal.

(5) On October 21, 2008, the JPO issued a trial decision dismissing the appellee's request for a trial, holding that since the Earlier Disposition had been issued, prior to the Disposition, with regard to the Earlier Pharmaceutical Disposition which has the same active ingredient as well as effect and efficacy as those of the Pharmaceutical Product, it is not found that it was necessary to obtain the Disposition for the working of the patented invention based on the Patent Right (this trial decision by the JPO shall hereinafter be referred to as the "JPO Decision").

3. Even in the case where, prior to the approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act, which gave rise to the necessity to file an application for registration of extension of the duration of a patent right (this approval shall hereinafter be referred to as the "later disposition"), another approval for manufacturing and sale under said paragraph (hereinafter referred to as the "earlier disposition") had been issued with regard to the pharmaceutical product which has the same active ingredient as well as effect and efficacy as those of the pharmaceutical product covered by the later disposition (the pharmaceutical product covered by the earlier disposition and that covered by the later disposition shall hereinafter be referred to as the "earlier pharmaceutical product" and "later pharmaceutical product," respectively), if the earlier pharmaceutical product is not included in the technical scope of the patented invention specified by any of the claims for the patent right pertaining to the application for registration of extension, it is unreasonable to deny that it was necessary to obtain the later disposition for the working of the patented invention based on said patent right, on the grounds of the existence of the earlier disposition. The purpose of the system of extension of the duration of a patent right is to reclaim the period of time during which the patentee has been unable to work the patented invention due to the necessity to obtain the disposition designated by Cabinet Order as set forth in Article 67, paragraph (2) of the Patent Act. Just because the earlier disposition had been issued with regard to the earlier pharmaceutical product which has the same active ingredient as well as effect and efficacy as those of the later pharmaceutical product, inasmuch as the earlier pharmaceutical product is not included in the technical scope of the patented invention specified by any of the claims for the patent right pertaining to the application for registration of extension, the existence of the earlier disposition does not mean that the patentee must have been able to work the patented invention based on the patent right pertaining to the application for registration of extension where the later pharmaceutical product constitutes the working of said patented invention, nor does it meant that the patentee must have been able to work the patented invention specified by any of the claims for said patent right. If the earlier pharmaceutical product is not included in the technical scope of the patented invention specified by any of the claims for the patent right pertaining to the application for registration of extension, this conclusion is not affected irrespective of how the scope of the effect of the patent right (Article 68-2 of the Patent Act) is defined in the case where the duration could have been extended because of the existence of the earlier disposition.

Since the Earlier Pharmaceutical Product is not included in the technical scope of the patented invention specified by any of the claims for the Patent Right, it is unreasonable to deny, in this case, that it was necessary to obtain the Disposition for the working of the patented invention, on the grounds of the existence of the Earlier Disposition.

4. For the reasons stated above, the ruling by the court of prior instance can be affirmed as justifiable in that the court found the JPO Decision to be illegal, holding that the existence of the Earlier Disposition cannot be the grounds for denying that it was necessary to obtain approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act for the working of the patented invention based on the Patent Right. We cannot accept the arguments for the final appeal.

Therefore, the judgment has been rendered in the form of the main text by the unanimous consent of the Justices.

(This translation is provisional and subject to revision.)